Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292Phase 2Recruiting
- Sponsor
- Servier
- Start
- Jul 2026
- Primary completion
- May 2033
- Countries
- 2
01
Overview
A Phase 2 trial of vorasidenib in astrocytoma, Oligodendroglioma (OG), sponsored by Servier. Started Jul 2026; status: recruiting.
02
Drugs
vorasidenib
03
Conditions
astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT07286292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286292.